Aptiva APS IgG Reagent and 1 more
System, Test, Anticardiolipin Immunological. 510(k) K223093, from Inova Diagnostics, Inc. (San Diego, CA). Product code MID, class 2.
As of Nov 19, 2026, K223093 is an FDA 510(k) held by Inova Diagnostics, Inc., substantially equivalent on Dec 17, 2024 after 809 days, with no recalls tied to it in FDA's recall database.
- Review time: 809 days
- Recalls: 0
The Aptiva APS IgG Reagent is an immunoassay utilizing particle-based multi-analyte technology for the semi- quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GPI) IgG autoantibodies in human serum as an aid in the diagnosis of primary and secondary antiphospholipid syndrome (APS), when used in conjunction with other laboratory findings.
- Hemosil Acustar Cardiolipin Igg, Igm and Igg and Igm ControlsK092181 · Instrumentation Laboratory CO · Mar 11, 2010
- Quanta Lite B2GPI IggK970551 · Inova Diagnostics, Inc. · Jun 24, 1997
- Hemosil Acustar ANTI-B2 Glycoprotein-I; Igg, Igm, Igg Controls, Igm ControlsK091556 · Instrumentation Laboratory CO · May 21, 2010
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Sep 30, 2022
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5660
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files